Compare Repligen Corporation Common Stock (RGEN) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Snap Inc — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Snap Inc trades at $6.05 (market cap $10.98B). The key difference: Repligen Corporation Common Stock and Snap Inc are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Snap Inc for 68 Days on average.
| RGEN | SNAP | |
|---|---|---|
Market Cap | $11.14B | $10.98B |
Volume | 1,259,263 | 53,140,165 |
Sector | Health | Media |
52-Week High | $194.57 | $9.09 |
52-Week Low | $102.87 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $11.02B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Snap Inc. (SNAP) trades at $6.10, down 6.73% over 24 hours, with technical indicators showing a bullish trend despite overbought RSI signals. The company reported revenue growth to $5.93B in 2025, though net losses persist at -$460M, with improving margins. Recent news highlights AI and AR developments, including SPECS glasses partnerships with NVIDIA and Salesforce, driving investor optimism amid regulatory pressures.
The outlook remains cautious; while analyst consensus is a $7.91 price target with 38% buy ratings, risks include sustained losses, high debt, and competitive threats. Upside hinges on monetizing AI innovations and achieving profitability, but volatility from sentiment shifts poses near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
